Clinical trial
Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia
NCT00391560 · AEterna Zentaris, Industry · Completed
Key facts
| NCT number | NCT00391560 |
|---|---|
| Title | Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia |
| Official title | Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia |
| Lead sponsor | AEterna Zentaris, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | perifosine |
| Enrollment | 19 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2011 |
| First posted | Oct 24, 2006 |
| Last update posted | Mar 14, 2018 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: